TERMINATION AND TRANSITION AGREEMENT DATED AS OF MARCH 18, 2013 BY AND AMONG NPS PHARMACEUTICALS, INC., TAKEDA GmbH, AND TAKEDA PHARMA A/STermination and Transition Agreement • March 19th, 2013 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS TERMINATION AND TRANSITION AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2013 (the “Effective Date”), by and among NPS Pharmaceuticals, Inc., a Delaware corporation (“NPS”), Takeda GmbH, a German company (formerly known as Nycomed GmbH) (“Takeda GmbH”), and Takeda Pharma A/S, a Danish company (formerly known as Nycomed Danmark ApS) (“Takeda Pharma” and, together with Takeda GmbH, “Takeda”). NPS and Takeda are sometimes referred to herein individually as a “Party” and together as the “Parties”.
For Immediate Release Contact:NPS Pharmaceuticals Inc • March 19th, 2013 • Biological products, (no disgnostic substances)
NPS Pharmaceuticals, Inc. Corporate Communications (908) 450-5516 smesco@npsp.com Takeda Pharmaceutical Company Limited Corporate Communications Dept. +81-3-3278-2037 Takeda Pharmaceuticals International GmbH +41445551501 tobias.cottmann@takeda.com
